Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy

2016 ◽  
Vol 63 ◽  
pp. 180-188 ◽  
Author(s):  
S. Lubberts ◽  
H. Boer ◽  
R. Altena ◽  
C. Meijer ◽  
A.M. van Roon ◽  
...  
1991 ◽  
Vol 19 (2) ◽  
pp. 125-131 ◽  
Author(s):  
S.D. Fosså ◽  
J.E. Melvik ◽  
N.O. Juul ◽  
E.O. Pettersen ◽  
Ø. Åmellem ◽  
...  

2006 ◽  
Vol 21 (11) ◽  
pp. 2882-2889 ◽  
Author(s):  
Loredana Gandini ◽  
Paolo Sgrò ◽  
Francesco Lombardo ◽  
Donatella Paoli ◽  
Franco Culasso ◽  
...  

2011 ◽  
Vol 98 ◽  
pp. S20
Author(s):  
M. Scharpfenecker ◽  
B. Floot ◽  
F. Stewart ◽  
N. Russell

Author(s):  
Massimo Franchini ◽  
Antonella Tufano ◽  
Aniello Casoria ◽  
Antonio Coppola

AbstractCancer is associated with an increased incidence of both venous thromboembolism (VTE) and arterial thrombosis (cardiovascular events and ischemic stroke). Cancer-associated arterial thrombotic events are less well studied than VTE, but increasingly recognized, particularly in specific malignancies and in association with specific anticancer therapies. The pathogenesis of arterial thrombotic events in cancer is complex and involves generation of tumor-associated procoagulant factors and a variety of alterations in platelet function as well as in the coagulation and fibrinolytic systems, and endothelial injury and dysfunction, that combine to produce hypercoagulability. The multifactorial interaction between this prothrombotic state, the individual cardiovascular risk, advanced age and presence of comorbidities, and the specific neoplasm characteristics and therapy, may induce the vascular events. Recent studies based on population databases and prospective or retrospective analyses with prolonged follow-up highlight that cancer patients experience an increased (approximately 1.5–2-fold) risk of both cerebrovascular and cardiovascular events compared with noncancer individuals, which peaks in the time period of the diagnosis of cancer but may persist for years. Beyond the type of cancer, the risk reflects the tumor burden, being higher in advanced stages and metastatic cancers. The occurrence of arterial thromboembolic events is also associated with increased overall mortality. We here present an update of the pathophysiology, risk factors, clinical evidence, and treatment considerations on cancer-associated arterial thrombosis, in the light of the need for specific multidisciplinary prevention and surveillance strategies in this setting, in the frame of cardio-oncology approaches.


1997 ◽  
Vol 78 (2) ◽  
pp. 120-123 ◽  
Author(s):  
R.H. Martin ◽  
S. Ernst ◽  
A. Rademaker ◽  
L. Barclay ◽  
E. Ko ◽  
...  

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Aisha Siebert ◽  
Jake Miller ◽  
Evan Panken ◽  
Gregory Auffenberg ◽  
Richard Fantus ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document